Hamad Mohamad A, Zajdowicz Sheryl L, Holmes Randall K, Voskuil Martin I
Department of Microbiology, University of Colorado School of Medicine, Mail Stop 8333, PO Box 6511, Aurora, CO 80045, USA.
Gene. 2009 Feb 1;430(1-2):123-31. doi: 10.1016/j.gene.2008.10.011. Epub 2008 Oct 28.
Burkholderia pseudomallei and B. mallei are Gram-negative bacterial pathogens that cause melioidosis in humans and glanders in horses, respectively. Both bacteria are classified as category B select agents in the United States. Due to strict select-agent regulations, the number of antibiotic selection markers approved for use in these bacteria is greatly limited. Approved markers for B. pseudomallei include genes encoding resistance to kanamycin (Km), gentamicin (Gm), and zeocin (Zeo); however, wild type B. pseudomallei is intrinsically resistant to these antibiotics. Selection markers for B. mallei are limited to Km and Zeo resistance genes. Additionally, there are few well developed counter-selection markers for use in Burkholderia. The use of SacB as a counter-selection method has been of limited success due to the presence of endogenous sacBC genes in the genomes of B. pseudomallei and B. mallei. These impediments have greatly hampered the genetic manipulation of B. pseudomallei and B. mallei and currently few reliable tools for the genetic manipulation of Burkholderia exist. To expand the repertoire of genetic tools for use in Burkholderia, we developed the suicide plasmid pMo130, which allows for the compliant genetic manipulation of the select agents B. pseudomallei and B. mallei using allelic exchange. pMo130 harbors an aphA gene which allows for Km selection, the reporter gene xylE, which allows for reliable visual detection of Burkholderia transformants, and carries a modified sacB gene that allows for the resolution of co-integrants. We employed this system to generate multiple unmarked and in-frame mutants in B. pseudomallei, and one mutant in B. mallei. This vector significantly expands the number of available tools that are select-agent compliant for the genetic manipulation of B. pseudomallei and B. mallei.
类鼻疽伯克霍尔德菌和鼻疽伯克霍尔德菌是革兰氏阴性细菌病原体,分别可导致人类患类鼻疽和马患鼻疽。这两种细菌在美国均被列为B类生物制剂。由于严格的生物制剂管理规定,被批准用于这些细菌的抗生素选择标记数量极为有限。批准用于类鼻疽伯克霍尔德菌的标记包括编码对卡那霉素(Km)、庆大霉素(Gm)和博来霉素(Zeo)耐药性的基因;然而,野生型类鼻疽伯克霍尔德菌对这些抗生素具有内在抗性。鼻疽伯克霍尔德菌的选择标记仅限于Km和Zeo抗性基因。此外,用于伯克霍尔德菌的成熟反选择标记很少。由于类鼻疽伯克霍尔德菌和鼻疽伯克霍尔德菌基因组中存在内源性sacBC基因,使用SacB作为反选择方法的成功率有限。这些障碍极大地阻碍了类鼻疽伯克霍尔德菌和鼻疽伯克霍尔德菌的基因操作,目前几乎没有用于伯克霍尔德菌基因操作的可靠工具。为了扩展用于伯克霍尔德菌的基因工具库,我们开发了自杀质粒pMo130,它允许使用等位基因交换对生物制剂类鼻疽伯克霍尔德菌和鼻疽伯克霍尔德菌进行合规的基因操作。pMo130含有一个允许进行Km选择的aphA基因、一个允许对伯克霍尔德菌转化体进行可靠视觉检测的报告基因xylE,并携带一个经过修饰的sacB基因,该基因可用于共整合体的拆分。我们利用该系统在类鼻疽伯克霍尔德菌中产生了多个无标记且符合读码框的突变体,在鼻疽伯克霍尔德菌中产生了一个突变体。该载体显著增加了可用于类鼻疽伯克霍尔德菌和鼻疽伯克霍尔德菌基因操作的、符合生物制剂管理规定的可用工具数量。